G Model FARMA-606; No. of Pages 4

ARTICLE IN PRESS

Farmacia Hospitalaria xxx (xxxx) xxx-xxx



Farmacia HOSPITALARIA Organo oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

FIGURE 1 TO SERVICE STATE OF THE SERVICE STATE OF T

www.elsevier.es/farmaciahospitalaria

Brief Report

Knowledge, perception, and willingness to implement the CMO methodology among specialist physicians caring for patients with HIV in Spain

Enrique Contreras Macías^{a,*}, Pilar Taberner Bonastre^b, Anaïs Corma Gómez^c, José Ramón Blanco Ramós and Ramón Morillo Verdugo^e

- ^a Servicio de Farmacia, Hospital San Juan de Dios Sevilla (Sevilla), Spain
- ^b Servicio de Farmacia, Hospital Universitario Arnau de Vilanova, Lleida, Spain
- ^c Servicio de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario Virgen de Valme (Sevilla), Spain
- d Servicio de Enfermedades Infecciosas, Hospital Universitario San Pedro-CIBIR (Logroño), Spain
- e Servicio de Farmacia, Hospital Universitario Virgen de Valme (Sevilla), Spain

ARTICLE INFO

Article history: Received 26 March 2025 Accepted 11 May 2025 Available online xxxx

Keywords: Pharmaceutical care Multidisciplinary integration Health outcomes Quality of Health Care

Palabras clave: Atención farmacéutica Integración multidisciplinar Resultados en salud Calidad de la Atención de Salud

ABSTRACT

Introduction: The CMO (Capability-Motivation-Opportunity) methodology is an innovative pharmaceutical care model designed to improve the quality of care for people living with HIV (PLWH). This approach evaluates the knowledge, perception, and willingness to implement the methodology among specialist physicians in Spain. Methods: This observational and descriptive study utilized a validated questionnaire distributed among clinicians involved in the care of PLWH. The survey assessed their knowledge and perception of the methodology. Associations between variables were analyzed using bivariate tests.

Results: Thirty physicians participated. Sixty percent reported moderate-to-high knowledge of the methodology, correlating with a positive perception of its clinical relevance (p=0.02). Motivational interviewing and remote follow-up were identified as key tools.

Conclusion: Knowledge of the CMO methodology is limited but positively valued. Its association with improved quality of health care underscores the importance of strategies to enhance its dissemination and adoption in clinical practice.

© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Conocimiento, percepción y disposición para implementar la metodología CMO entre médicos especialistas que atienden a pacientes con VIH en España

RESUMEN

Introducción: La metodología CMO (Capacidad-Motivación-Oportunidad) es un modelo innovador de atención farmacéutica diseñado para mejorar la calidad asistencial en las personas que viven con VIH (PVV). Este enfoque analiza el conocimiento, percepción y predisposición para su implementación entre médicos especialistas en España.

Métodos: Estudio observacional y descriptivo que empleó un cuestionario validado, distribuido entre clínicos dedicados a PVV, que exploró el conocimiento y la percepción sobre la metodología. Las asociaciones entre variables se evaluaron mediante pruebas bivariantes.

Resultados: Se incluyeron 30 médicos. Un 60% reportó un conocimiento moderado-alto de la metodología, asociándolo con una percepción positiva por su relevancia clínica (p = 0,02). La entrevista motivacional y el seguimiento remoto fueron valorados como herramientas clave.

https://doi.org/10.1016/j.farma.2025.05.007

1130-6343/© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article as: Contreras Macías E, et al.. Knowledge, perception, and willingness to implement the CMO methodology among specialist physicians caring for patients with HIV in Spain. Farmacia Hospitalaria. 2025. https://doi.org/10.1016/j.farma.2025.05.007

^{*} Corresponding author.

E-mail addresses: enrique.contreras@sjd.es (E. Contreras Macías), ptaberner.lleida.ics@gencat.cat (P. Taberner Bonastre), jrblanco@riojasalud.es (J.R. Blanco Ramos).

ARTICLE IN PRESS

E. Contreras Macías, P. Taberner Bonastre, A. Corma Gómez et al.

Farmacia Hospitalaria xxx (xxxx) xxx-xxx

Conclusión: El conocimiento de la metodología CMO es limitado, pero positivamente valorado. Su asociación con la mejora de la calidad de la atención sanitaria subraya la importancia de implementar estrategias para fomentar su difusión y adopción en la práctica clínica.

© 2025 Los Autores. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

The optimal clinical outcomes of antiretroviral therapy (ART) have transformed HIV infection into a chronic condition, presenting significant challenges associated with aging, such as the emergence of age-related comorbidities and polypharmacy. In this context, one of the priorities in the care of people living with HIV (PLWH) is the development of interventions aimed at improving health outcomes, particularly quality of life. ²

In the field of Hospital Pharmacy (HP), the increasing number of patients served in outpatient clinics, together with the evolving profile of PLWH, also poses challenges. These challenges are influenced by significant variability in care delivery, prompting the Spanish Society of Hospital Pharmacy (SEFH) to implement initiatives that enable a structured, collaborative, and consensus-driven response among healthcare professionals.³ To this end, in 2014, the project "Strategic Map for Pharmaceutical Care for Outpatients" (MAPEX-SEFH) was launched, focusing on multidisciplinary and multidimensional pharmaceutical care (PC) characterized by excellence in knowledge, evaluation of outcomes, and an anticipatory approach to future needs.³

One of the most significant advances of this project has been the redefinition of the concept of PC itself.⁴ Within this framework, the capacity-motivation-opportunity (CMO) Pharmaceutical Care Model was designed to address three major identified care needs: individualized care based on a multidimensional approach; a professional orientation focused on achieving pharmacotherapeutic objectives; and longitudinal monitoring to ensure continuity of care.⁵

Since its development in 2016, the CMO methodology has proven to be an effective strategy for improving clinical outcomes and the quality of life of PLWH, as evidenced by various high-impact multicenter studies. This methodology has been associated with significant improvements in patient experience, adherence to ART, virological control, and management of comorbidities. These outcomes support its adoption as a reference standard for care, grounded in multidisciplinary collaboration. However, its implementation has not been uniform across the national territory due to various factors, including limited awareness among other healthcare professionals regarding the potential health benefits it can offer. September 2016.

The objective of this study was to evaluate the level of knowledge, perception, and willingness to implement the CMO methodology among medical specialists caring for PLWH in Spain.

Methods

This observational, descriptive, and cross-sectional study was conducted in two phases between June and December 2024.

In the first phase, a specific questionnaire was designed based on a systematic review of the scientific literature related to the CMO methodology and its applicability in healthcare contexts. The questionnaire included items aimed at exploring key dimensions such as knowledge of the methodology, its perceived relevance, and the willingness to adopt it. Content validation was performed by an expert committee to ensure the relevance and clarity of the selected items. Responses were classified into three categories: low, 1-4 moderate, 5-7 and high. 7-10

The second phase involved anonymous data collection. The questionnaire was distributed through SEFH's mailing list to its members,

who were encouraged to share the invitation to participate with clinicians at their respective centers. The questionnaire was hosted on an electronic platform and distributed via the SEFH mailing list, with participation restricted to physicians who received a prior invitation to ensure a representative focus on the target population.

The target population consisted of medical specialists actively managing PLWH in Spain. Inclusion criteria were limited to physicians who completed the questionnaire in its entirety, while those with incomplete responses or who did not meet the established criteria were excluded.

A descriptive analysis of the participants' baseline characteristics was performed, with categorical variables expressed as absolute frequencies and percentages. Additionally, bivariate analyses were conducted to assess associations among physicians with knowledge of the CMO model, using the Chi-square test or Fisher's exact test, as appropriate. A high level of knowledge was defined as responses indicating moderate-to-high familiarity in the question, "How would you rate your knowledge of the CMO methodology?" Statistical significance was set at p < 0.05. The analysis was performed using SPSS statistical software, version 26 (IBM Corp., Armonk, NY, USA).

The study protocol and all relevant documentation were reviewed and approved by the South Seville Research Ethics Committee (code SICEIA-2024-000342).

Results

A total of 30 participants were included, 60% of whom were male. Table 1 summarizes the baseline characteristics and questionnaire responses.

Knowledge of the CMO methodology was moderate-to-high in 60% of participants. This group demonstrated statistically significant differences in their perception of the importance of implementing PC based on this methodology compared to those with low knowledge (p = 0.02). Furthermore, participants with greater knowledge believed that implementing the methodology could improve both quality of life (p < 0.01) and health outcomes (p = 0.12). Table 2 provides the complete results of the bivariate analysis.

Regarding the different pillars of the CMO model, **90%** of respondents considered stratification to be of high importance. Additionally, 86.7% rated motivational interviewing as highly beneficial, with greater appreciation observed among participants with more advanced knowledge of the methodology. Remote monitoring of PLWH via telemedicine and/or telepharmacy was deemed highly relevant by 73.3% of respondents.

Discussion

This study demonstrates that the CMO methodology is positively valued by medical specialists, although general knowledge about it remains limited.

The level of knowledge about the CMO model is directly associated with a greater perception of its clinical relevance and an increased willingness to implement it. This finding aligns with the principle of lifelong learning, widely recognized as fundamental for ensuring professional competence and optimizing pharmacotherapeutic and healthcare

ARTICLE IN PRESS

E. Contreras Macías, P. Taberner Bonastre, A. Corma Gómez et al.

Farmacia Hospitalaria xxx (xxxx) xxx-xxx

Table 1Baseline Characteristics of Study Participants and Questionnaire Responses.

Male; n(%) Autonomous community Andalusia 5 (16.7) Aragon 1 (3.3) Catalonia 7 (23.3) Extremadura 1 (3.3) Galicia 2 (6.7) La Rioja 1 (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country (3.3) Valencia 1 (3.3) Basque Country (4.3) Basque Coun			
Autonomous community Andalusia 5 (16.7) Aragon 1 (3.3) Catalonia 7 (23.3) Extremadura 1 (3.3) Galicia 2 (6.7) La Rioja 1 (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country 1 (3.3) Basque Country 1 (3.3) Valencia 1 (3.3) Basque Country 1 (3.3) Basque Country 1 (3.3) Valencia 1 (3.3) Basque Country 1 (40) Medium 1 (3.6) Low 1 (4.6) Medium (4.6) Medium (4.6) High 1 (6.0) High 2 (6.6) High 2 (6.6) High			N = 30
Autonomous community Andalusia 5 (16.7) Aragon 1 (3.3) Catalonia 7 (23.3) Extremadura 1 (3.3) Galicia 2 (6.7) La Rioja 1 (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country 1 (3.3) Basque Country 1 (3.3) Valencia 1 (3.3) Basque Country 1 (3.3) Basque Country 1 (3.3) Valencia 1 (3.3) Basque Country 1 (40) Medium 1 (3.6) Low 1 (4.6) Medium (4.6) Medium (4.6) High 1 (6.0) High 2 (6.6) High 2 (6.6) High	Malar a (9/)		10 (00)
Aragon (astile and León (13.3) Castile and León (13.3) Catalonia (13.3) Extremadura (13.3) Galicia (26.7) La Rioja (13.3) Madrid (9.30) Murcia (13.3) Basque Country (13.3) Basque Country (13.3) Valencia (13.3) Age (13.3)			
Castile and León 7 (23.3) Extremadura 1 (3.3) Galicia 2 (6.7) La Rioja 1 (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country 1 (3.3) Valencia 1 (3.3) So Jo years 12 (40) Vears of experience in caring for PLWH 5 years 7 (23.3) 5-10 years 12 (47) Vears of experience in caring for PLWH 5 years 7 (23.3) So Jo years 12 (40) Vears 22 (73.3) So Jo years 12 (40) Vears 1 (3.3) Vour low as yis your level of Low 11 (36.6) Vear Well with the CMO methodology? How low low ledge regarding the available publications on the application of the methodology is: How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels today High 12 (70) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels today High 26 (86.1) High 18 (60) Low 0 (13.3) High 18 (60) Wedium 14 (46.2) Wedium 14 (46.2)	Autonomous community	Andalusia	
Catalonia 7 (23.3) Extremadura 1 (3.3) Galicia 2 (6.7) La Rioja 1 (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country 1 (3.3) Basque Country 1 (3.3) Age 30–50 years 18 (60) S50 years 12 (40) Years of experience in caring for PLWH 55 years 7 (23.3) S10 years 12 (40) Years of experience in caring for PLWH (5.5) years 7 (23.3) S10 years 22 (73.3) How many PLWH do you attend in a month? (100 4 (13.3) 100–300 18 (60) S300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? High 4 (13.3) What would you say is your level of knowledge with the CMO methodology? Medium 15 (50) High 4 (13.3) What would you say is your level of the methodology is: High 4 (13.3) How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider patient stratification at both the medical and pharmaceutical levels today? How important do you consider patient stratification at both the medical and pharmaceutical levels today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 27 (90) How important do you consider patient stelepharmacy) today? High 26 (86.5) High 27 (90) High 27 (90) Hoderate 8 (26.7) High 27 (90) High 28 (80.6) High 29 (80.6) High 20 (80.6) Hig			1 (3.3)
Extremadura 1 (3.3) Galicia 2 (6.7) La Rioja 1 (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country 1 (3.3) Valencia 1 (3.2) Valencia 1 (3.3) Valencia 1 (3.3) Valencia 1 (3.4) Valencia 1 (3.3) Valencia 1 (3.4) Valencia 1 (3.3) Valencia 1 (3.4) Val			1 (3.3)
Galicia 1 (3.3) La Rioja 1 (3.3) Madrid 9 (30) Murcia 1 (3.3) Basque Country 1 (3.3) Valencia 1 (3.3) Age 30–50 years 12 (40) Years of experience in caring for PLWH 5 years 7 (23.3) Folyears 7 (23.3) Folyears 1 (3.3) Folyears 7 (23.3) Folyears 2 (27.3) How many PLWH do you attend in a month? 100 4 (13.3) What would you say is your level of familiarity with the CMO methodology? 100–300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? 100–300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? 100–300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? 100–300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? 100–300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? 100–300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? 100–300 8 (26.7) What would you believe it is to apply famaceutical Care according to the CMO methodology to woll improve the quality of life for patients today? 100–300 8 (26.7) How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? 100–300 8 (26.7) How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? 100–300 8 (26.7) How important do you consider patient stratification at both the medical and pharmaceutical levels today 100–300 8 (26.7) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? 100–300 8 (26.7) High 18 (60) Low 0 (31.0) Low 0 (31.0) 100–300 8 (26.7) Medium 15 (50) Medium 16 (46.3) High 18 (60) Low 10 (33.3) Moderate 8 (26.7) High 27 (90) Low 0 (31.0) 100–300 8 (26.7) High 26 (86.7) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical le		Catalonia	7 (23.3)
Galicia 1 (3.3) I Age 30–50 years 18 (60) Years of experience in caring for PLWH 5 years 7 (23.3) How many PLWH do you attend in a month? 6 years 7 (23.3) How many PLWH do you attend in a month? 6 years 7 (23.3) How many PLWH do you attend in a month? 6 years 7 (23.3) How was year 7 (23.3) How was year 7 (23.3) 100–300 18 (60) 300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? Medium 15 (50) High 4 (13.3) What would you say is your level of knowledge with the CMO methodology? Medium 14 (46.1) High 4 (13.3) Your level of knowledge regarding the available publications on the application of the methodology is: High 4 (13.3) How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How wimportant do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) High 27 (90) How important do you consider remote patient monitoring (telemedicinetiendical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicinetiendical and pharmaceutical levels) today? High 26 (86.7) High 26 (86.7) High 27 (90) High 27		Extremadura	1 (3.3)
La Rioja (13.3) Madrid (9 (30) Madrid (9 (30) Madrid (13.3) Basque Country (13.3) Age (13.3) Age (13.3) Age (13.3) Age (13.3) Shasque Country (13.3) Valencia (13.3) Age (13.3) Shasque Country (13.3) Valencia (13.3) Age (13.3) Shasque Country (13.3) Valencia (13.3) Shasque Country (13.3) Valencia (13.3) Shasque Country (13.3) Valencia (13.3) Shasque Country (13.3) S		Galicia	
Age 30-50 years 12 (40) Years of experience in caring for PLWH 50 years 12 (40) Years of experience in caring for PLWH 50 years 12 (40) Years of experience in caring for PLWH 50 years 12 (40) Years of experience in caring for PLWH 50 years 12 (40) Years of experience in caring for PLWH 50 years 12 (33) So Jo years 12 (33) So Jo years 12 (40) Years 61 years 7 (23.3) So 100 years 12 (33) So 100 years 12 (40) What would you say is your level of 100 100 11 (36.7) In grain 100 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you say is your level of 100 11 (36.7) What would you believe it is to apply 100 11 (36.7) What would you believe it is to apply 100 11 (36.7) What would you believe it is to apply 100 11 (36.7) What would you believe it is to apply 100 11 (36.7) What would you believe it is to apply 100 11 (36.7) What would you believe the implementation of 100 11 (36.7) What would you believe it is to apply 100 11 (36.7) What would you believe the implementation of 100 11 (36.7) What would you believe the implementation of 11 (36.7) What would you believe the implementation of 11 (36.7) What would you be willing to or encourage your 100 11 (36.7) Would you be willing to or encourage your 100 11 (36.7) Would you be willing to or encourage your 100 11 (36.7) Would you be willing to or encourage your 100 11 (36.7) Would you be willing to or encourage your 100 11 (36.7) Would you believe it would bring any benefits at 100 10 (36.7)			
Age 30–50 years 18 (60) 50 years 12 (40) Years of experience in caring for PLWH 55 years 7 (23.3) 5–10 years 13 (3.3) 10 years 22 (73.3) 100–300 18 (60) 300 8 (26.7) 100–300 18 (60) 300 8 (26.7) 11 (33.3) 10 years 22 (73.3) 100–300 18 (60		•	
Age 30-50 years 18 (60) Years of experience in caring for PLWH 550 years 7 (23.3) How many PLWH do you attend in a month? 5-10 years 22 (73.3) How many PLWH do you attend in a month? 100-300 18 (60) 300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? Medium 15 (50) High 4 (13.3) What would you say is your level of knowledge with the CMO methodology? Medium 14 (46. High 4 (13.3) Your level of knowledge regarding the available publications on the application of the methodology is: How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology Outliamprove the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the althoutouromes for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels today High 27 (90) High 26 (86.3) High 27 (90) High 27 (9			
Age 30–50 years 18 (60)			
Age			
Years of experience in caring for PLWH 50 years 7 (23.3) 5-10 years 100 4 (13.3) 100-300 18 (60) 300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? Medium 15 (50) High 4 (13.3) What would you say is your level of knowledge with the CMO methodology? Medium 16 (40) Knowledge with the CMO methodology? Medium 17 (36) What would you say is your level of knowledge with the CMO methodology? Medium 18 (46) What would you say is your level of knowledge with the CMO methodology? Medium 19 (40) Medium 11 (36) High 4 (13.3) What would you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine- telepharmacy) today? How important do you consider remote patient monitoring (telemedicine- telepharmacy) today? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No			, ,
Years of experience in caring for PLWH 5 years 5-10 years 22 (73.3) 100-300 18 (60) 300 8 (26.7) What would you say is your level of familiarity with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you be great in the available publications on the application of the methodology is: How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider mente patient monitoring (telemedicinetielepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefit	Age		
How many PLWH do you attend in a month? Solution S		>50 years	12 (40)
How many PLWH do you attend in a month? 100	Years of experience in caring for PLWH	<5 years	7 (23.3)
How many PLWH do you attend in a month? 100–300		5-10 years	1 (3.3)
How many PLWH do you attend in a month? 100–300		>10 years	22 (73.3)
What would you say is your level of familiarity with the CMO methodology? What would you say is your level of familiarity with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? What would you say is your level of Low 12 (40) What would you say is your level of Low 12 (40) What would you say is your level of Low 14 (46.3) What would you say is your level of knowledge regarding the low 11 (36.3) High 11 (36.3) High 5 (16.7) How important do you believe it is to apply Low 3 (10) Pharmaceutical Care according to the CMO Moderate 9 (30) Methodology today? How do you believe the implementation of Low 2 (6.7) Pharmaceutical Care according to the CMO Moderate 10 (33.3) Pharmaceutical Care according to the CMO Moderate 8 (26.7) Moderate 8 (26.7) What would you consider patient Low 0 Stratification at both the medical and pharmaceutical levels today? How important do you consider patient Low 0 Stratification at both the medical and pharmaceutical levels today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? Is the CMO methodology applied in practice in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0	How many PLWH do you attend in a month?	•	
What would you say is your level of familiarity with the CMO methodology? Medium High High 4 (13.3] What would you say is your level of knowledge with the CMO methodology? Medium High 4 (13.3] What would you say is your level of knowledge with the CMO methodology? Medium High 4 (13.3) Your level of knowledge regarding the available publications on the application of the methodology is: How important do you believe it is to apply Low Moderate High 1 (36.7) High 4 (13.3) High 5 (16.7) How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How important do you consider patient outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational low Interviewing in consultations (both at the medical and pharmaceutical levels) today? High 20 (86.5) High 20 (86.6) High 21 (100) 21 (100) 21 (100) 22 (100) 23 (100) 24 (100) 25 (100) 26 (100) 26 (100) 26 (100) 26 (100) 27 (100) 28 (100) 29 (100) 20 (100) 2			
What would you say is your level of familiarity with the CMO methodology? Medium 15 (50) High 4 (13.3) What would you say is your level of Low 12 (40) knowledge with the CMO methodology? Medium 14 (46.5 High 4 (13.3) Your level of knowledge regarding the available publications on the application of the methodology is: High 5 (16.7) High 13 (10.0) High 15 (16.7) How important do you believe it is to apply Low 3 (10) Pharmaceutical Care according to the CMO methodology today? High 18 (60) High 18 (60) High 18 (60) life for patients today? How do you believe the implementation of life for patients today? How do you believe the implementation of life for patients today? How do you believe the implementation of life for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 21 (70) High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.5 How important do you consider remote patient monitoring (telemedicinetelepharmacy) today? High 26 (86.5 High 22 (73.5 Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 16 (33.3) Moderate 16 (42.1) High 20 (66.5 (42.1) High 20 (66.5 (42.1) High 20 (66.5			
familiarity with the CMO methodology? What would you say is your level of knowledge with the CMO methodology? Medium 14 (46. High 4 (13.3) 4 (13.	M/hat would was any in your lavel of		
What would you say is your level of knowledge with the CMO methodology? Medium 12 (40) High 4 (13.3) Your level of knowledge regarding the available publications on the application of the methodology is: How important do you believe it is to apply harmaceutical Care according to the CMO methodology today? High 18 (60) How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote patient monitoring (telemedicinetelepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 11 (57.9) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center, in the CMO methodology at your center, what is your level of satisfaction? High 20 (66. mag) (6			
What would you say is your level of knowledge with the CMO methodology? Medium 14 (46.) Your level of knowledge regarding the available publications on the application of the methodology is: High 5 (16.7) How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? High 18 (60) Moderate 9 (30) Moderate 9 (30) Moderate 10 (33.) Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels today? High 26 (86.) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.) How important do you consider remote Low 0 patient monitoring (telemedicinetelepharmacy) today? High 26 (86.) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in High 20 (66.) case it is not currently applied)? Do you believe it would bring any benefits at No 0	familiarity with the CMO methodology?		
knowledge with the CMO methodology? Medium		•	
Your level of knowledge regarding the available publications on the application of the methodology is: High 1 (46.7) How important do you believe it is to apply Pharmaceutical Care according to the CMO Moderate 9 (30) methodology today? High 18 (60) How do you believe the implementation of Pharmaceutical Care according to the CMO Moderate 10 (33.3) methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO Moderate 10 (33.3) Pharmaceutical Care according to the CMO Moderate 10 (33.3) Pharmaceutical Care according to the CMO Moderate 10 (33.3) Pharmaceutical Care according to the CMO Moderate 8 (26.7) How do you believe the implementation of Low 1 (3.3) Pharmaceutical Care according to the CMO Moderate 8 (26.7) How important do you consider patient Low 0 ostratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote Low 0 medical and pharmaceutical levels) today? High 26 (86.7) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your Low 1 (3.3) Pharmaceutical colleagues to implement Moderate 9 (30) Moderate 9 (30)			
Your level of knowledge regarding the available publications on the application of the methodology is: How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicinetelepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement Moderate 9 (30) To deficit the Medium 1 (46.5) Medium 4 (13.3) Medium 4 (13.3) Medium 4 (13.3) Medium 8 (26.7) High 26 (86.7) I don't know 12 (40) Low 0 Moderate 8 (26.7) I don't know 12 (40) I don't know 12 (40) Low 0 Moderate 8 (42.1) I don't know 12 (40) I don't know 12 (40) Moderate 9 (30) Moderate 9 (30)	knowledge with the CMO methodology?	Medium	14 (46.7)
available publications on the application of the methodology is: How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement case it is not currently applied)? Do you believe it would bring any benefits at No 0		High	4 (13.3)
available publications on the application of the methodology is: How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement case it is not currently applied)? Do you believe it would bring any benefits at No 0	Your level of knowledge regarding the	Low	14 (46.7)
the methodology is: How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine- telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? Is the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at High 2 (10.7) Moderate High 1 (20.66.7) High 2 (10.7) How Moderate 1 (3.3) High 2 (3.3) High 2 (3.3) How important do you consider remote Low 0 (3.3) Medium 4 (13.3) High 2 (3.6) H		Medium	
How important do you believe it is to apply Pharmaceutical Care according to the CMO methodology today? High 18 (60) How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine- telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? Is the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at Low 0 In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 20 (66.5)			
Pharmaceutical Care according to the CMO methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? Is the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement Moderate 9 (30) To would believe it would bring any benefits at No 0			
methodology today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicinetelepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement Moderate 9 (30) Would believe the implement and to Moderate 10 (3.3.) Low 0 13 (43.3.) Woderate 8 (42.1.) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement Moderate 9 (30) Do you believe it would bring any benefits at No 0			
How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No			
Pharmaceutical Care according to the CMO methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0		-	
methodology could improve the quality of life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement Moderate 9 (30) (86.5) High 18 (26.7) High 27 (90) Low 0 In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement Moderate 9 (30) (86.5) High 20 (66.5)			
life for patients today? How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0 1 (3.3)	Pharmaceutical Care according to the CMO	Moderate	10 (33.3)
How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0	methodology could improve the quality of	High	18 (60)
How do you believe the implementation of Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0	life for patients today?		
Pharmaceutical Care according to the CMO methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0		Low	1 (3.3)
methodology could improve health outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0		Moderate	
outcomes for patients today? How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0			
How important do you consider patient stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0		111611	21 (70)
stratification at both the medical and pharmaceutical levels today High 27 (90) How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote Low 0 patient monitoring (telemedicine-telepharmacy) today? High 22 (73.7) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case if is not currently applied)? Do you believe it would bring any benefits at No 0		I	0
pharmaceutical levels today How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0 heddium 4 (13.3) Medium 8 (26.7) High 22 (73.3) I don't know 12 (40) Low 0 I (3.4) I don't know 12 (40) Low 0 I (3.3) Moderate 8 (42.1) Low 1 (3.3)			
How important do you consider motivational interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 11(57.9) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0			
interviewing in consultations (both at the medical and pharmaceutical levels) today? High 26 (86.7) How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0		•	
medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine- telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at High 26 (86.7 High 27 (86.7 Yes 16 (16.7) Yes 1 don't know 12 (40) 10 (40) 11 (3.3) 11 (3.3) 11 (3.3) 12 (3.3) 13 (3.3) 14 (3.3) 15 (40) 16 (16.7) 16 (16.7) 17 (17 (18) 18 (19) 19 (19) 10 (19) 11 (19) 12 (19) 13 (19) 14 (19) 15 (19) 16 (19) 17 (19) 18 (19) 19 (19) 10 (19) 11 (19) 11 (19) 12 (19) 13 (19) 14 (19) 15 (19) 16 (19) 17 (19) 18 (19) 19 (19) 10 (19) 11 (19) 11 (19) 12 (19) 13 (19) 14 (19) 15 (19) 16 (19) 17 (19) 18 (19) 19 (1		Low	0
medical and pharmaceutical levels) today? How important do you consider remote patient monitoring (telemedicine- telepharmacy) today? Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at High 26 (86.7 High 27 (86.7 Yes 16 (16.7) Yes 1 don't know 12 (40) 10 (40) 11 (3.3) 11 (3.3) 11 (3.3) 12 (3.3) 13 (3.3) 14 (3.3) 15 (40) 16 (16.7) 16 (16.7) 17 (17 (18) 18 (19) 19 (19) 10 (19) 11 (19) 12 (19) 13 (19) 14 (19) 15 (19) 16 (19) 17 (19) 18 (19) 19 (19) 10 (19) 11 (19) 11 (19) 12 (19) 13 (19) 14 (19) 15 (19) 16 (19) 17 (19) 18 (19) 19 (19) 10 (19) 11 (19) 11 (19) 12 (19) 13 (19) 14 (19) 15 (19) 16 (19) 17 (19) 18 (19) 19 (1	interviewing in consultations (both at the	Medium	4 (13.3)
How important do you consider remote patient monitoring (telemedicine-telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 11(57.9) (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0		High	26 (86.7)
patient monitoring (telemedicine- telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40.7) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 11(57.9) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 13 (43.3) Moderate 8 (42.1) Low 1 (3.3) Moderate 9 (30)	How important do you consider remote	Low	0
telepharmacy) today? High 22 (73.3) Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? I don't know 12 (40) In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 11(57.9) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0		Medium	8 (267)
Is the CMO methodology applied in practice in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 13 (43.3) 13 (43.3) Yes 5 (16.7) I don't know 12 (40) Moderate 8 (42.1) High 11(57.9) 13 (43.3) Moderate 9 (30.3)			
in daily patient care at your center, either fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 12 (40) 12 (40) 13 (40) 14 (40) 15 (40) 16 (42.1) 16 (5) 16 (6) 17 (7) 18 (7) 19 (8) 10 (8) 11 (57.9) 11 (3.3) 12 (3.3)		-	
fully or partially? In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 12 (40) Moderate 8 (42.1) Low 1 (3.3) 1 (3.3) Moderate 9 (30) 1 (3.6) 1 (40) Moderate 9 (42.1) 1 (57.9) 1 (57.9) 1 (58.1) 1 (59.1) 1 (59.2) 1 (59.2) 1 (59.2) 1 (59.2) 1 (59.2) 1 (59.2) 1 (40) 1 (40) 1 (40) 1 (40) 1 (3.1) 1 (59.2) 1 (5	is the CWO methodology applied in practice		
In the case of having any practical experience in applying the CMO methodology at your center, what is your level of satisfaction? High 11(57.9 (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0			
in applying the CMO methodology at your center, what is your level of satisfaction? High 11(57.9 (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0	fully or partially?		, ,
center, what is your level of satisfaction? (N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 1 (3.3) Moderate 9 (30) High 20 (66.3)	In the case of having any practical experience		
(N = 19) Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 0 (3.3)		Moderate	8 (42.1)
Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 1 (3.3) Low 1 (3.3) Moderate 9 (30) High 20 (66.3)	center, what is your level of satisfaction?	High	11(57.9)
Would you be willing to or encourage your pharmaceutical colleagues to implement the CMO methodology at your center (in case it is not currently applied)? Do you believe it would bring any benefits at No 1 (3.3) Low 1 (3.3) Moderate 9 (30) High 20 (66.3)	(N = 19)		
pharmaceutical colleagues to implement Moderate 9 (30) the CMO methodology at your center (in High 20 (66.3) case it is not currently applied)? Do you believe it would bring any benefits at No 0	,	Low	1 (3.3)
the CMO methodology at your center (in High 20 (66.7 case it is not currently applied)? Do you believe it would bring any benefits at No 0			
case it is not currently applied)? Do you believe it would bring any benefits at No 0			
Do you believe it would bring any benefits at No 0		High	20 (00.7)
	* ** *	No	0
4h			
	the medical level?		30 (100)
I don't know 0		I don't know	Ü

outcomes in dynamic healthcare settings.^{10,11} These results are consistent with previous studies highlighting the integration of innovative models that can significantly improve inter-level care quality and therapeutic outcomes.^{12,13}

However, the findings also reveal considerable heterogeneity in the adoption of the model. Despite the recognition of fundamental pillars and tools such as care stratification as critical for improving health outcomes, their practical application remains nascent and insufficient. 14,15

 Table 2

 Results of the Bivariate Analysis Based on Knowledge of the CMO Methodology.

		No (n = 12)	Yes (n = 18)	P-value
Your level of knowledge	Low	11 (91.7)	3 (16.7)	<0.01
about the available publications on the	Medium High	1 (8.3) 0	10 (55.6) 5 (27.8)	
application of the	ingn	Ü	3 (27.0)	
methodology is:		0 (0=)		
How important do you believe it is to apply	Low Moderate	3 (25) 5 (41.7)	0 4 (22.2)	0.02
Pharmaceutical Care	High	4 (33.3)	14 (77.8)	
according to the CMO				
methodology in today's context?				
How do you believe the	Low	2 (16.7)	0	< 0.01
implementation of	Moderate	()	3 (16.7)	
Pharmaceutical Care according to the CMO	High	3 (25)	15 (83.3)	
methodology could				
improve patients' quality				
of life today? How do you believe the	Low	1 (8.3)	0	0.12
implementation of	Moderate		3 (16.7)	
Pharmaceutical Care	High	6 (50)	15 (83.3)	
according to the CMO methodology could				
improve health outcomes				
for patients today?				
How important do you consider patient	Low Medium	0 2 (16.7)	0 1 (5.6)	0.32
stratification at both the	High	10 (83.3)	17 (94.4)	
medical and				
pharmaceutical levels today				
How important do you	Low	0	0	0.13
consider motivational	Medium	3 (25)	1 (5.6)	
interviewing in consultations (both at the	High	9 (75)	17 (94.4)	
medical and				
pharmaceutical levels) today?				
How important do you	Low	0	0	0.12
consider remote patient	Medium	5 (41.7)	3 (16.7)	
monitoring (telemedicine- telepharmacy) today?	High	7 (58.3)	15 (83.3)	
Is the CMO methodology	No	2 (16.7)	11 (61.1)	< 0.01
applied in practice in daily	Yes	1 (8.3)	4 (22.2)	
patient care at your center, either fully or partially?	I don't know	9 (75)	3 (16.7)	
In the case of having any	Low	0	0	0.08
practical experience in	Moderate	5 (100)	8 (57.1)	
applying the CMO methodology at your	High	0	6 (42.9)	
center, what is your level of				
satisfaction?		1 (0.0)	•	0.53
Would you be willing to encourage your	Low Moderate	1 (8.3) 6 (50)	0 3 (16.7)	0.04
pharmaceutical colleagues	High	5 (41.7)	15 (83.3)	
to implement the CMO				
methodology at your center (in case it is not				
currently applied)?				
Do you believe it would bring		0	0	0.01
any benefits at the medical level?	Yes I don't	12 (100) 0	18(100) 0	
	know			

Integrating pharmacists into care teams emerges as a key strategy to ensure the effective implementation of the CMO model. Successful experiences have shown how active pharmacist participation contributes to optimizing multidisciplinary management, improving treatment adherence, and increasing patient satisfaction. ⁶ This level of multidisciplinary collaboration is essential for addressing the complex needs of PLWH and achieving a positive impact on patient health outcomes.

ARTICLE IN PRESS

E. Contreras Macías, P. Taberner Bonastre, A. Corma Gómez et al.

Farmacia Hospitalaria xxx (xxxx) xxx-xxx

A crucial strategy for overcoming the observed variability could involve the development of training programs for both physicians and pharmacists, focusing on the practical benefits of the CMO model, particularly in key areas such as stratification, motivational interviewing, and telehealth. Additionally, pilot initiatives integrating this methodology into specific contexts could facilitate its progressive adoption.

This study has several limitations, including its cross-sectional design and the use of a self-administered questionnaire. Nevertheless, the study design accounted for these circumstances, and the methodology aimed to ensure sample representativeness and minimize potential biases associated with the self-selective nature of participation. Employing complementary methodologies, such as semi-structured interviews or focus groups, could enhance understanding of the barriers and facilitators to adopting this model. Future research should focus on longitudinal designs and evaluating the impact of specific interventions aimed at promoting model implementation.

In conclusion, the CMO model represents an innovative opportunity to transform PC. The widespread implementation of this model, supported by national educational strategies, the integration of information technologies, and the promotion of standardized practices, has the potential to improve health outcomes and care quality. This approach can consolidate a patient-centered, excellence-oriented care paradigm aligned with the strategic objectives of the MAPEX project.

Declaration of authorship

The corresponding author, on behalf of all authors, certifies that:

- Each of the persons indicated as authors has made a direct and significant contribution to the intellectual content of the work.
- 2. All authors have reviewed and approved the contents of the manuscript submitted to the editorial process.
- 3. Each of them has given their consent for their name to appear in the authorship of the manuscript.

CRediT authorship contribution statement

Enrique Contreras Macías: Writing – review & editing, Writing – original draft, Visualization, Validation, Investigation, Formal analysis, Data curation. Pilar Taberner Bonastre: Writing – review & editing, Visualization, Validation, Methodology, Investigation. Anaïs Corma Gómez: Writing – review & editing, Visualization, Validation, Methodology. José Ramón Blanco Ramos: Writing – original draft, Visualization, Validation, Supervision, Investigation, Conceptualization. Ramón Morillo Verdugo: Writing – review & editing, Visualization, Validation, Supervision, Investigation, Conceptualization.

Ethical considerations

The study protocol and any other relevant documentation were reviewed and approved by the Research Ethics Committee of Sevilla Sur (code SICEIA-2024-000342).

Funding

The authors declare that they have not received any funding for the development of the study.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

- Guaraldi G, Milic J, Gnoatto Perondi E, Rodrigues Gonçalves AC, Mussini C, de Avila Vitoria MA, et al. The UN decade of healthy aging (2021–30) for people living with HIV. Lancet Healthy Longev. 2024;5(11):100643. doi:10.1016/j.lanhl.2024.100643.
- Behr LC, Simm A, Kluttig A, Großkopf A. 60 years of healthy aging: on definitions, biomarkers, scores and challenges. Aging Res Rev. 2023;88:101934. doi:10.1016/j. arr.2023.101934.
- 3. El proyecto MAPEX. Documentación [Internet]. [consultado el 15 de enero de 2025]. Disponible en: https://www.sefh.es/mapex/documentacion.php.
- Morillo-Verdugo R, Calleja-Hernández MÁ, de Las Aguas Robustillo-Cortés M. A new pharmaceutical care concept: more capable, motivated, and timely. Hosp Pharm. 2019:54(6):348–50. doi:10.1177/0018578719867657.
- Calleja Hernández MA, Morillo Verdugo R. El modelo CMO en consultas externas de Farmacia Hospitalaria [Internet]. [consultado el 15 de enero de 2025]. Disponible en: https://www.sefh.es/sefhpdfs/Libro_CMO.pdf.
- Sánchez-Yáñez E, Huertas-Fernández MJ, Robustillo-Cortés MA, Ramos-Guerrero R, Fernández-Espínola S, Díaz-Acedo R, et al. Application of CMO (capacity, motivation, and opportunity) methodology in pharmaceutical care to optimize the pharmacotherapy in older people living with HIV. DISPIMDINAC project. Rev Esp Quimioter. 2023;36(6):584–91. doi:10.37201/req/021.2023.
- Morillo-Verdugo R, Lázaro-López A, Alonso-Grandes E, Martín-Conde MT, Díaz-Ruiz P, Molina-Cuadrado E, et al. Patient experience evaluation of the CMO-based pharmaceutical care model vs usual care in people living with HIV. J Multidiscip Healthc. 2022;15:2991–3003. doi:10.2147/JMDH.S392398.
- Vicente-Escrig E, Bonastre PT, Barrueta OI, Izquierdo MM, Fernández-Llamazares CM, Morillo-Verdugo R. Analysis 2016–2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain. Farm Hosp. 2024;48(2):T64–9.
- De la Torre-Lima J, Oteo JA, Pinilla J, Mansilla R, Zamora C, Ayala Vargas V, et al. Study on the approach to HIV: health management and the healthcare process in Spain. Enferm Infecc Microbiol Clin (Engl Ed). 2023;41(10):604–11. doi:10.1016/j. eimce.2022.12.008.
- Maggiolo F, Lo Caputo S, Bonora S, Borderi M, Cingolani A, D'Ettorre G, et al. Optimizing the antiretroviral treatment focusing on long-term effectiveness and a personcentered approach. Consensus guidance using a Delphi process. New Microbiol. 2024;46(4):367–80.
- Cordero-Cruz AM, Fernández de Gamarra-Martínez E, Florencio M, González-Haba E, Marcos JA, Molina García T, et al. Conquering the future in hospital pharmacy: training as a pillar of success. Farm Hosp. 2024;48(Suppl 1):TS45–51. doi:10.1016/j.farma 2024 06 009
- Giddings R, Indravudh P, Medley GF, Bozzani F, Gafos M, Malhotra S, et al. Infectious disease modeling of HIV prevention interventions: a systematic review and narrative synthesis of compartmental models. Pharmacoeconomics. 2023;41(6):693–707. doi: 10.1007/s40273-023-01260-z.
- 13. Martínez-Sanz J, Losa-García JE, Orozco N, Alastrué I, Mascort J, Pérez-Elías MJ, et al. Grupo de trabajo de atención compartida en VIH (Sociedad Española de medicina de familia y comunitaria semFYC y grupo de estudio del sida de la sociedad Española de enfermedades infecciosas y microbiología clínica GeSIDA SEIMC). Executive summary of the consensus document on the shared care of patients with HIV infection between primary and hospital care. Enferm Infecc Microbiol Clin (Engl Ed). 2024;42(2):102–7. doi:10.1016/j.eimce.2023.05.009.
- Suárez-Robles M, Crespillo Andújar C, Chamorro-Tojeiro S, Monge-Maillo B, Norman F, Peña I, et al. Real-life application of a stratification model for HIV care. Enferm Infecc Microbiol Clin (Engl Ed). 2025;43(2):80–5. doi:10.1016/j.eimce.2024.05.008.
- Morillo-Verdugo R, Álvarez A, Monte-Boquet E, Vélez M, Margusino L, Sánchez E, et al. Proyecto de adopción y puesta en valor del modelo CMO [Internet]. Sociedad Española de Farmacia Hospitalaria. 2025 [consultado el 15 de enero de 2025]. Disponible en: https://www.sefh.es/mapex/images/modelo-cmo-proyecto-adopcion-puesta-en-valor.pdf.